Document is current
Any future updates will be listed below
-
Authors
Paladino, Andrew J.
Pebley, Kinsey
Kocak, Mehmet
Krukowski, Rebecca A.
Waters, Teresa M.
Vidal, Gregory
Schwartzberg, Lee S.
Curry, Andrea N.
Graetz, Ilana
-
Funding
Funding for this research was provided by:
National Cancer Institute (1R01CA218155, 1R01CA218155, 1R01CA218155, 1R01CA218155, 1R01CA218155, 1R01CA218155, 1R01CA218155)
- License Information
-
More Information
Article History
Received: 14 June 2022
Revised: 11 October 2022
Accepted: 19 October 2022
First Online: 23 November 2022
Declarations
:
: The protocol for the study has been reviewed and approved by the UTHSC Institutional Review Board (#17–05479-XP IAA). Informed consent was obtained from all study participants. All methods were carried out in accordance with Declaration of Helsinki.
: Not applicable.
: Dr. Vidal reported receiving personal fees from Roche/Genetech, Eli Lilly, Pfizer, AstraZeneca, Myriad and research funding from Roche/Genetech, Puma, Celcuity, Merck, BMS, Eli Lilly, Astrazeneca, Gilead, GSK, and ownership of Oncodisc. Dr. Schwartzberg reported receiving personal fees from Pfizer, Helsinn, AstraZeneca, Genentech, Myriad, Bayer, Napo, Eli Lilly, BeyondSpring Pharmaceuticals, Abbvie, Coherus Biosciences, Illumina, Sanofi, Mirati Therapeutics, GlaxoSmithKline, and research support from Amgen, Pfizer. Dr. Graetz received research support from Pfizer. No other disclosures were reported.
